Eli Lilly reports findings from ADjoin extension trial of Ebglyss

New results show Eli Lilly’s (LLY) Ebglyss sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks, supporting a potential additional, less frequent maintenance dosing option for more individualized treatment of patients with moderate-to-severe atopic dermatitis. These findings from the Phase 3 ADjoin extension trial will be presented at the 2025 Fall Clinical Dermatology Conference, taking place Oct. 23-26 in Las Vegas. The ADjoin extension study, results indicate that maintenance dosing every other month demonstrated similarly high rates of disease control compared to monthly dosing: 79% of patients taking Ebglyss once every other month and 86% of patients taking EBGLYSS monthly, respectively, achieved or maintained EASI 75. 62% of patients taking Ebglyss once every other month and 73% of patients taking Ebglyss monthly, respectively, achieved or maintained IGA 0,1. There was no increased risk of immunogenicity and no new safety findings. These data support that once every eight-week Ebglyss dosing could give HCPs and patients a new treatment option using the lowest effective dose. Lilly has submitted these data from the ADjoin extension trial among other data to the FDA for a potential label update. A study investigating Ebglyss maintenance dosing of 500 mg administered once every 12 weeks is underway.